⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4574975 | 0.81 | — | — | |
| SCHEMBL3703321 | 0.70 | — | — | |
| SCHEMBL3701156 | 0.69 | — | — | |
| SCHEMBL2507943 | 0.69 | — | — | |
| SCHEMBL334983 | 0.63 | — | — | |
| SCHEMBL3708196 | 0.62 | — | — | |
| SCHEMBL3707605 | 0.60 | CXCR4 (0.30) | — | |
| SCHEMBL596656 | 0.59 | — | — | |
| Aziridine SCHEMBL7968853 | 0.56 | — | — | |
| Aziridine SCHEMBL28198451 | 0.56 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 202 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3288939-A1 | TRICYCLIC MODULATORS OF TNF SIGNALING | AbbVie Inc. (US) | 2018-03-07 | — | — | EP | claimed |
| US-9856253-B2 | Tricyclic modulators of TNF signaling | ABBVIE, INC. (US) | 2018-01-02 | — | — | US | claimed |
| US-20160304517-A1 | TRICYCLIC MODULATORS OF TNF SIGNALING | ABBVIE INC. | 2016-10-20 | — | — | US | claimed |
| WO-2016168641-A1 | TRICYCLIC MODULATORS OF TNF SIGNALING | ABBVIE INC. (US) | 2016-10-20 | — | — | WO | claimed |
| US-20150025058-A1 | 8 - SUBSTITUTED 2 -AMINO - [1,2,4] TRIAZOLO [1, 5 -A] PYRAZINES AS SYK TRYROSINE KINASE INHIBITORS AND GCN2 SERIN KINASE INHIBITORS | MERCK PATENT GMBH (DE) | 2015-01-22 | — | — | US | claimed |
| EP-1558595-B1 | PIPERAZINYL AND DIAZAPANYL BENZAMIDES AND BENZTHIOAMIDES | JANSSEN PHARMACEUTICA NV (BE) | 2009-11-25 | — | — | EP | claimed |
| WO-2009131246-A1 | SORDARIN DERIVATIVES FOR PREVENTING OR TREATING INFECTIOUS DISEASES CAUSED BY PATHOGENIC MICROORGANISMS | ASTELLAS PHARMA INC. (JP) | 2009-10-29 | — | — | WO | claimed |
| US-20080056991-A1 | PIPERAZINYL AND DIAZAPANYL BENZAMIDES AND BENZTHIOAMIDES | APODACA RICHARD L | 2008-03-06 | — | — | US | claimed |
| US-20070072837-A1 | Phenylalkynes | APODACA RICHARD | 2007-03-29 | — | — | US | claimed |
| EP-1451167-B1 | PHENYLALKYNES | ORTHO MCNEIL PHARM INC (US) | 2006-03-08 | — | — | EP | claimed |
| EP-1451167-A1 | PHENYLALKYNES | Ortho-McNeil Pharmaceutical, Inc. (US) | 2004-09-01 | — | — | EP | claimed |
| US-20040110746-A1 | Piperazinyl and diazapanyl benzamides and benzthioamides | JANSSEN PHARMACEUTICA N.V. (BE) | 2004-06-10 | — | — | US | claimed |
| US-20040087573-A1 | Phenylpiperidines and phenylpyrrolidines | JANSSEN PHARMACEUTICA N.V. (BE) | 2004-05-06 | — | — | US | claimed |
| US-20040002604-A1 | Phenylalkynes | ORTHO-MCNEIL PHARMACEUTICAL, INC. | 2004-01-01 | — | — | US | claimed |
| US-20030144323-A1 | For treatment of disorders and conditions mediated by the histamine receptor; allergies, sleep disorders, dementia | ORTHO-MCNEIL PHARMACEUTICAL, INC. | 2003-07-31 | — | — | US | claimed |
| WO-2003050099-A1 | PHENYLALKYNES | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2003-06-19 | — | — | WO | claimed |
| WO-2024150146-A1 | ENGINEERED KETOREDUCTASE POLYPEPTIDES | NOVARTIS AG (CH) | 2024-07-18 | — | — | WO | disclosed |
| WO-2023238078-A1 | (S)-ENGINEERED OXYNITRILASE POLYPEPTIDES AND USES THEREOF | NOVARTIS AG (CH) | 2023-12-14 | — | — | WO | disclosed |
| US-5462934-A | Cholinesterase inhibitor; learning enhancement | TAKEDA CHEMICAL INDUSTRIES (JP) | 1995-10-31 | — | — | US | disclosed |
| EP-0560235-A1 | Condensed heterocyclic ketone derivatives, their production and use | Takeda Chemical Industries, Ltd. (JP) | 1993-09-15 | — | — | EP | disclosed |